Merck is shopping for biotech deals, CEO says
Merck & Co. is "actively looking" to partner with or acquire biotech companies valued at "single-digit" billions of dollars, although a takeover similar to its purchase of Schering-Plough is "off the table right now," CEO Richard Clark said. The drugmaker will first review the Merck-Schering pipeline before deciding on therapeutic areas in which to expand, Clark said.
Wall Street Journal, The | 11/05
This story published in BIO SmartBrief on 11/05/2009
More from SmartBrief:
Merck finalizes $41 billion merger with Schering-Plough
Wednesday, November 4, 2009
Niacin outperforms Zetia in study of cholesterol treatments
Monday, November 16, 2009
Most execs to come from Merck after merger with Schering
Tuesday, September 1, 2009
Get stories like these delivered daily for FREE:
|
BIO SmartBrief
Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more |
|